Human CXCL10/IP‑10/CRG‑2 Biotinylated Antibody

CXCL10 was originally identified as an IFN-gamma -inducible gene in monocytes, fibroblasts, and endothelial cells. It has since been shown that CXCL10 mRNA is also induced by LPS, IL-1 beta, TNF-alpha, IL-12, and viruses. Additional cell types that have been shown to express CXCL10 include activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. CXCL10 is also expressed in psoriatic and lepromatous lesions of skin. The mouse homologue of human CXCL10, CRG-2, has been cloned and shown to share approximately 67% amino acid (aa) sequence identity with human CXCL10. Human CXCL10 cDNA encodes a 98 aa residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted protein. The amino acid sequence of CXCL10 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CXCL10 has been shown to be a chemoattractant for activated T-lymphocytes. CXCL10 has been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent anti-tumor effect. A chemokine receptor specific for CXCL10 and MIG has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.